WELLCOVORIN
LOE ApproachingNDAORALTABLET
Approved
Jul 1983
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
WELLCOVORIN is an oral small-molecule tablet approved in 1983 by GSK. The mechanism of action and specific indications are not publicly detailed in available data, limiting clinical characterization. It is a legacy NDA product now in late lifecycle stages.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), suggesting contracted commercial team focus and transition planning activities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
WELLCOVORIN currently shows zero linked job openings, reflecting its mature LOE-approaching lifecycle. Career roles on this product center on defensive commercial execution, managed decline, and transition planning rather than growth initiatives.
Brand ManagerField Sales Representative
Worked on WELLCOVORIN at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.